1. What Sanofi might buy with its Regeneron windfall — Gilead pens $2B Arcus pact for immuno-oncology targets — FDA approves BMS Opdivo + Yervoy combo for first-line on certain types of NSCLC — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Comp plan

Discussion in 'Covidien' started by anonymous, Jun 18, 2018 at 3:11 PM.

  1. anonymous

    anonymous Guest

    This has got to be a joke.
     
  2. anonymous

    anonymous Guest

    Not what you were hoping for?
     
  3. anonymous

    anonymous Guest

    No. I was hoping that we'd focus on clinically differentiated products but, instead, my comp is going to be held hostage by me too crap commodities like AI & ES. Forget tip of the spear, this is more like blunt end of the club. I guess the BOHICA strategy was on the money.
     
  4. anonymous

    anonymous Guest

    “Clinically differentiated products”.....that’s funny.
     
  5. anonymous

    anonymous Guest

    And the hots just at keep on keepin on.